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Abstract
Background: Hazardous and harmful alcohol use and high blood pressure are central risk factors related to premature
non-communicable disease (NCD) mortality worldwide. A reduction in the prevalence of both risk factors has been
suggested as a route to reach the global NCD targets. This study aims to highlight that screening and interventions for
hypertension and hazardous and harmful alcohol use in primary healthcare can contribute substantially to achieving the
NCD targets.
Methods: A consensus conference based on systematic reviews, meta-analyses, clinical guidelines, experimental studies,
and statistical modelling which had been presented and discussed in five preparatory meetings, was undertaken.
Specifically, we modelled changes in blood pressure distributions and potential lives saved for the five largest
European countries if screening and appropriate intervention rates in primary healthcare settings were increased.
Recommendations to handle alcohol-induced hypertension in primary healthcare settings were derived at the conference,
and their degree of evidence was graded.
Results: Screening and appropriate interventions for hazardous alcohol use and use disorders could lower blood pressure
levels, but there is a lack in implementing these measures in European primary healthcare. Recommendations included (1)
an increase in screening for hypertension (evidence grade: high), (2) an increase in screening and brief advice on
hazardous and harmful drinking for people with newly detected hypertension by physicians, nurses, and other
healthcare professionals (evidence grade: high), (3) the conduct of clinical management of less severe alcohol use
disorders for incident people with hypertension in primary healthcare (evidence grade: moderate), and (4) screening for
alcohol use in hypertension that is not well controlled (evidence grade: moderate). The first three measures were
estimated to result in a decreased hypertension prevalence and hundreds of saved lives annually in the examined
countries.
Conclusions: The implementation of the outlined recommendations could contribute to reducing the burden associated
with hypertension and hazardous and harmful alcohol use and thus to achievement of the NCD targets. Implementation
should be conducted in controlled settings with evaluation, including, but not limited to, economic evaluation.
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Background
Alcohol and hypertension as risk factors for non-
communicable diseases (NCDs)
In May 2013, the World Health Organization (WHO)
adopted a Global Action Plan for the Prevention and
Control of Non-communicable Diseases for the period
2013–2020. The main target [1] comprises a 25% reduc-
tion in the risk of premature mortality from cardiovascular
diseases, cancer, diabetes, or chronic respiratory diseases.
To achieve this overall target, a number of individual tar-
gets for risk factors have been established, including, but
not limited to, at least a 10% reduction in the harmful use
of alcohol and a 25% reduction in the prevalence, or limita-
tion of the increase in the prevalence, of raised blood pres-
sure (BP), according to national circumstances. For
countries of the European Union, given the consistently
high rates of raised BP over the past decades (e.g., [2]), the
25% reduction of prevalence seems most appropriate [3].
It has been estimated that, if the main targets for risk
factors were to be achieved, the overall goal for reduction
of premature mortality would be practically reached at the
global level [4], and would be exceeded in the European
region [5]. The measures proposed to reach the NCD
goals are centered around the so-called “best buys” of the
WHO, interventions that are not only highly cost-effective
but also feasible and appropriate to implement within the
respective health systems [6]. Best buys for alcohol com-
prise taxation increases, restrictions on availability, and a
ban on marketing for alcohol use. For hypertension, best
buys were more scarce, as only a reduction of salt intake
was listed (Appendix 3 of reference [1]) [6–8]. Herein, we
will show, using data from five European countries, that
screening and interventions for both hazardous and harm-
ful use of alcohol (including alcohol use disorders (AUDs))
and for hypertension in primary healthcare can also lead
to public health-relevant reductions of NCDs in Europe,
albeit at higher costs than best buys (see point on eco-
nomic considerations below), as these are individual-level
interventions. In addition, this paper will list recommen-
dations from a consensus conference on what should be
performed to achieve these reductions.
Methods
Herein, the various stages in preparation for and the activ-
ities performed at the consensus conference on “Screening
and intervention for harmful alcohol use as a tool to im-
prove the management of hypertension in primary care” will
be outlined. The conference took place in Barcelona on
12th November, 2015, by invitation of the Public Health
Agency of Catalonia (see Additional file 1: Appendix 1 for
the agenda). Catalonia is one of the few jurisdictions in Eur-
ope which has integrated yearly screening for alcohol con-
sumption into its primary healthcare plan. The Public
Health Agency prepared the conference [9].
Input into the conference
In preparation for the conference, a number of national
meetings on its topic were held in Belgium [10], Finland
[11], Germany [12], Spain [13], and the UK [14], where
presentations of systematic reviews and meta-analyses
on causality and the relationship between drinking and
BP (see below for a summary) and of systematic reviews
on the effects of alcohol intervention on BP (see below
for a summary) were held. Further, modelling of the po-
tential impact of primary care interventions on alcohol
(technical details on the modelling are listed in Ap-
pendix 2, following the stipulations of the GATHER state-
ment [15]) was performed and the results from a survey
among primary care physicians on practices concerning al-
cohol screening and interventions in the management of
hypertension [16] were presented. Finally, draft recommen-
dations, prepared on the basis of the abovementioned
national meetings, were put forward.
Steps towards consensus
Each draft recommendation was discussed extensively
with a preliminary wording. It was agreed that the prelim-
inary wordings would be circulated again to all partici-
pants to achieve a final consensus, together with new
evidence as available. The second consultation period took
place between 20th September and 20th October, 2016.
As part of the revision process for the journal article, new
evidence was incorporated and there was a third consult-
ation between February 16th and March 1st, 2017.
Grading the recommendations
We based our recommendations on the GRADE (Grading
of Recommendations Assessment, Development and Evalu-
ation) approach, which rates the quality of evidence for a
particular outcome across studies and does not rate the
quality of individual studies [17, 18]. For some recommen-
dations, we took the evidence grades from the respective
review of UK National Institute for Heath and Care Excel-
lence (NICE), which used the same system to grade the
quality of evidence as high, moderate, low, or very low [19].
Results and Discussion
The evidence for alcohol interventions to reduce BP
Several systematic reviews and meta-analyses have shown
that alcohol consumption and hypertension are linked in a
dose-dependent fashion [20–23], although there may be a
threshold level for alcohol consumption below which
there are no effects, especially for women [24, 25] (for in-
direct evidence see [26]). As indicated by the potential
threshold, the dose-response relationship is not linear over
the full range of alcohol consumption, but for both sexes
there is a monotonic dose-response relationship for higher
levels of consumption [20, 22, 24], and thus hazardous/
harmful drinking and AUDs are closely associated with
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elevated BP and/or hypertension [23, 27, 28]. The above
described association between hazardous/harmful alcohol
consumption and hypertension has been judged as causal
[29–31], which means that a logical intervention to reduce
BP is to reduce alcohol consumption.
Indeed, several studies support the efficacy and effective-
ness of interventions to decrease alcohol consumption in
reducing BP levels, with a clinically meaningful decline in
BP occurring within a few weeks after reductions in alcohol
intake among hypertensive patients [30, 32, 33]. The most
comprehensive systematic review and meta-analyses on the
effect of alcohol consumption on BP in trials lasting at least
7 days (median duration: 4 weeks) found that, above a base-
line drinking level of two drinks per day (drink size was as-
sumed to be 12 g pure alcohol), reduction in alcohol
intake was associated with BP reduction [34]. The higher
the alcohol consumption at baseline, the greater the re-
duction in alcohol consumption and in BP levels. The ef-
fect could also be shown for people with hypertension
[34]. The evidence supporting this intervention is of the
highest possible grade [35], as it is based on a systematic
review and meta-analyses of randomized controlled trials
of interventions to reduce BP in both normotensives and
hypertensives, with adequate control groups (for the im-
portance of control groups specifically in the area of inter-
ventions for lowering BP see the paper by Patel et al. [36]).
The available evidence has led to standard formulations
in European and Canadian guidelines for the management
of hypertension in the past decades to address lifestyle fac-
tors, including alcohol [37, 38]. In fact, most guidelines,
including those from the NICE, stipulate that all patients
undergoing assessment or treatment for hypertension
should receive initial and periodic lifestyle advice, which
includes ascertaining their alcohol consumption and en-
couraging a reduced intake if they drink hazardously [39].
The situation in the US is slightly different. Although
American Society of Hypertension Community Guide-
lines briefly mention the contribution of alcohol to
raised BP [40], the association between alcohol con-
sumption and raised BP is not even mentioned in the
main national hypertension guidelines [41] or in the
American College of Cardiology/American Heart Asso-
ciation Guidelines regarding lifestyle management to re-
duce cardiovascular risk [42].
Interventions to reduce alcohol consumption
In the primary care settings, there is significant overlap
of hazardous drinking/AUDs (for background see [43])
and hypertension. European evidence suggests that
20.6% of hypertensive men aged 40–65 years have an
AUD and 16.7% have alcohol dependence. For hyperten-
sive women aged 40–65 years, it is estimated that 7.2%
have an AUD and 5.8% have alcohol dependence [12].
Adding these people to those who do not qualify for an
AUD diagnosis but drink above 60 g or 40 g of pure al-
cohol per day (for men and women, respectively), re-
sulted in 30.9% or 20.0% of men and women aged 40–65
years, respectively, qualifying for alcohol interventions
with hypertension. Compared to those without any
AUD, patients with an AUD are estimated to have a 1.5-
to 5-fold increased risk of hypertension, with the highest
risks for hypertension involving higher levels of alcohol
consumption [44–46]. In the above-cited study of more
than 13,000 patients in primary healthcare [28, 47], the
age-adjusted odds ratio (OR) for hypertension in the age
group 40–64 years was 1.59 among those diagnosed with
AUD by the treating general practitioner (95% CI 1.35–
1.88, P < 0.001; own calculations – see Additional file 2:
Appendix 2) [47–49].
Looking at the odds from hypertension in the cited
study, the age-adjusted OR for an AUD was, of course,
similar (OR 1.60, 95% CI 1.35–1.88, P < 0.001) because
of the symmetry property of OR, and the odds of quali-
fying for an intervention among people with hyperten-
sion was 1.35 (95% CI 1.12–1.58, P < 0.001; own
calculations; for a description of the study see [47–49]).
Since a reduction in alcohol consumption leads to a
decline in BP levels [32, 34], the question becomes
whether effective interventions to reduce alcohol con-
sumption are available in primary healthcare. There is
ample evidence, based on randomized controlled trials
in many countries, that screening and brief advice are ef-
fective in reducing alcohol consumption in hazardous
and harmful drinkers [50], and that effective psychother-
apies and pharmacotherapy plus psychosocial interven-
tions are effective in reducing consumption levels in
dependent drinkers [51–55]. Despite this evidence, and
its inclusion in some guidelines [37, 39], interventions to
reduce alcohol consumption do not play a major role in
the management of hypertension at the primary health-
care level in many European countries [16, 56]. One ex-
ample that illustrates the paucity of activity in primary
healthcare is the recent five-country Optimizing Delivery
of Health Care Interventions study that recruited 120
primary healthcare units from Catalonia, England,
Netherlands, Poland, and Sweden [57]. During the 4-
week baseline measurement period, in only 1202 out of
179,954 adult consultations (0.67%) were patients
screened for and advised about their hazardous drinking.
Studies have identified a number of potential barriers
to the adoption of screening and brief advice in primary
healthcare, including the lack of resources, training and
support from management, as well as workload [58, 59].
Given this situation, experts in several countries have
started to take steps towards better integration of alco-
hol interventions in primary healthcare [10–14]. Despite
obvious differences between healthcare systems, there
are clear commonalities in the recommendations made
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by the different sets of national experts. These recom-
mendations focus on providing incentives for screening
and treatment, better education for primary healthcare
providers regarding the link between alcohol and hyper-
tension, and the inclusion of simple alcohol tools in elec-
tronic patient records, such that the management of
alcohol use becomes standard practice for all patients
with hypertension.
The potential in Europe – examples from five countries
While control and management of hypertension is a key
element of any European guideline for primary healthcare,
most general population surveys show that a large minor-
ity of women and the majority of men with hypertension
aged 40 to 64 either do not know about their health con-
dition or are not adequately controlled (i.e., they show BP
values ≥ 140/90 mm Hg; see Table 1 for details).
The following models the joint effects of two interven-
tions (see Additional file 2: Appendix 2). First, it is as-
sumed that 50% of the people aged 40–64 years with
uncontrolled hypertension (i.e., BP ≥ 140/90 mm Hg [37,
60, 61]) receive an intervention (in part but not limited
to pharmacotherapy [37]), which lowers their BP level to
that of people with controlled hypertension. Secondly, it
is assumed that, among those with uncontrolled hyper-
tension who are receiving hypertension interventions,
50% of those eligible will also receive either brief advice
or a brief intervention for hazardous or harmful alcohol
use, or treatment for alcohol dependence. The results
are summarized in Table 2.
In each of the countries, the proposed intervention
would have a sizeable effect on improving BP levels
among 40- to 65-year-old hypertensives and would
markedly increase the proportion of people below the
threshold 140/90 mm Hg in the general population (for
men, between 1.5% and 5.3%; for women, between 1.0%
and 2.0%). Both effects are more pronounced in men,
which is not surprising, as men have worse control of
BP in all countries and, relatedly, they have worse alco-
hol consumption habits [1] (Table 2).
The next set of calculations measures the impact of
the proposed interventions on mortality and burden of
disease as measured in disability-adjusted live years
(DALYs) in the same age group within 1 year, using the
methodology of comparative risk assessment [62, 63]
(see Additional file 2: Appendix 2). This limitation for
1 year is consistent with knowledge that brief interven-
tion effects will show some attrition over time [64].
The potential effect of the interventions on reducing
mortality would be sizeable. In each of the five countries
examined, the reductions of BP and the effects of reduced
alcohol would lead to hundreds of deaths avoided within
1 year (Table 3); for instance, in Germany alone, a reduc-
tion of 1536 cardiovascular disease deaths, 138 gastro-
intestinal deaths, and 20 injury deaths. In terms of burden
of disease, for Germany, about 86,000 years of life lost due
to cardiovascular premature mortality or due to disability
in this age group could be avoided, plus another 5500 due
to gastrointestinal disease and 3000 due to injury.
This does not even include the effect of reduced alco-
hol use on other disease categories such as AUDs or
cancer. For the latter disease category, the effects would
only be seen after decades due to the long time lag [65].
For the other disease categories, lag times are short [66],
and the vast majority of deaths will be covered, includ-
ing liver cirrhosis deaths, where interventions have
shown immediate effects [67].
Recommendations
1) Increase screening for hypertension in primary
healthcare.
Evidence grade: High. Despite control of
hypertension being an integral part of primary
healthcare in most European countries, a measurable
proportion of the patients with undetected
hypertension is evident in all countries, usually
among the younger age groups (see Table 1 for
details for the five countries modelled). As a result,
many countries make specific recommendations for
Table 1 Proportion with hypertension with or without control in large population surveys among 40–64 year olds
Proportion of people with hypertensiona Proportion recognized or in treatment (with or without adequate control)b Fieldwork of
main studyWomen Men Women Men
France 30.4% 46.2% 64.0% 36.1% 2006–2007
Germany 29.6% 36.5% 56.0% 40.1% 2008–2011
Italy 33.2% 42.1% 52.0% 40.4% 2008–2012
Spain 30.0% 42.0% 62.0% 48.1% 2008–2010
UK 22.6% 27.2% 31.2% 23.9% 2006
For definitions and sources, see Additional file 2: Appendix 2
aHypertension was defined by a blood pressure ≥ 140/90 mm Hg or by being on hypertensive medication
bNeither recognition nor initiation of hypertension treatment implies that the patient is adequately controlled (i.e., below 140/90 mm Hg). The number of people
without adequately controlled hypertension among those recognized/treated varies from country to country and usually exceeds the number of people with
adequate control
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Table 2 Blood pressure indicators among people with hypertension before and after the interventions among people with
hypertension, 40–64 years old
Sex Mean systolic BPa Δb %≥ 140/90 mm Hga Δc General
populationdbefore after before after
France W 140.7 138.1 2.5 48% 41% 7% 2.0%
M 146.3 141.0 5.3 59% 48% 11% 5.3%
Germany W 141.5 138.5 3.0 49% 42% 7% 2.0%
M 143.9 139.8 4.2 55% 45% 9% 3.4%
Italy W 144.7 142.1 2.6 56% 51% 6% 1.8%
M 144.2 139.7 4.4 55% 45% 10% 4.0%
Spain W 146.0 144.6 1.4 60% 57% 3% 1.0%
M 146.8 144.9 1.9 62% 57% 4% 1.8%
UK W 141.5 139.5 2.0 50% 45% 5% 1.1%
M 145.4 142.8 2.5 58% 52% 5% 1.5%
For definitions and sources, see Additional file 2: Appendix 2 [109]
aBlood pressure (BP) in mm Hg among people with hypertension, defined by a BP ≥ 140/90 mm Hg or by being on hypertensive medication
bDifference between before and after interventions in mm Hg
c% difference between before and after interventions
d% increase of people below the threshold of 140/90 mm Hg in the general population
Table 3 Lives saved and disability-adjusted life years avoided in major disease categories within 12 months attributable to the inter-
ventions among people with hypertension, 40–64 years old
Deaths Cardiovascular disease Gastrointestinal disease
Total Attributable to IHD Attributable to stroke Total Attributable to liver cirrhosis Injury
France W 111 25 47 12 11 3
M 1041 443 276 109 88 30
Germany W 275 83 98 25 22 2
M 1261 633 246 113 100 18
Italy W 158 42 57 10 9 1
M 805 389 180 98 82 15
Spain W 50 16 22 4 3 1
M 301 164 76 48 38 8
UK W 77 27 29 25 24 2
M 378 220 78 84 75 11
DALYs
France W 10,590 2850 5189 456 417 418
M 56,844 23,237 19,335 4235 3710 2914
Germany W 21,179 7042 8703 1007 943 599
M 64,840 31,245 16,983 4491 4022 2379
Italy W 15,543 4948 5872 489 452 536
M 47,273 21,992 13,020 4305 3777 2491
Spain W 4764 1483 2100 181 159 233
M 16,419 8086 5007 1934 1660 1198
UK W 4860 1648 2117 1012 936 495
M 18,354 9581 5348 3394 3033 1632
For definitions and sources, see Additional file 2: Appendix 2
IHD ischemic heart disease, DALYs disability-adjusted life years
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the screening of hypertension via regular
measurement of BP (for example, for the UK see the
Quality and Outcomes Framework indicator set by
the National Health Service; for underlying evidence
see reviews [68–70] or large trials [71]). The
evidence for these screening efforts was graded as
the highest possible quality, and current explorations
are mainly concerned with best techniques for
assessing BP [68, 72].
2) Increase screening and brief advice on hazardous and
harmful drinking for people with newly detected
hypertension from physicians, nurses, and other
healthcare professionals in primary healthcare.
Evidence grade: High. Even though this
recommendation has not been implemented into
clinical practice in most countries, the evidence
grade from controlled clinical studies has been
evaluated as consistently high (see [50, 64, 73] for
effectiveness of brief advice for reducing drinking;
see [32, 34] for meta-analyses of alcohol interventions
on BP, including on BP levels of people with
hypertension).
3) Treatment for less severe alcohol use disorders in
people with incident hypertension should be
conducted in primary healthcare, including but not
limited to pharmacologically assisted treatment.
Evidence grade: Moderate. While there are some
recommendations for treatment of less severe
AUDs in primary healthcare [74–76] and
randomized controlled trials on specific elements
of this strategy (e.g., effectiveness of medication-
assisted treatment [77, 78]), the strategy has not
been systematically tested in randomized controlled
clinical trials. Additionally, to date, it has not been
tested specifically for people with hypertension in
primary healthcare, even though there is evidence
from randomized controlled trials that treatment
for AUDs can lower BP [33, 79–81]. This is to
be expected, as AUDs are strongly associated
with hazardous or harmful drinking levels [43,
82], and abstinence or reduction of drinking is
the main outcome variable in most of these
trials [83].
4) Screen for alcohol use in hypertension that is not well
controlled.
Evidence grade: Moderate. Current guidelines for
the management for treatment-resistant hyperten-
sion, comprising approximately 8–12% of patients
with uncontrolled BP [84], emphasize screening of
alcohol use and reduction of hazardous or harmful
drinking levels [85, 86]. However, there are no ran-
domized clinical trials underlying this
recommendation; it is supported mainly by biological
plausibility and, in a recent assessment [86], the
relevant committee of the French Society for
Hypertension gave it a moderate evidence grade.
Economic considerations
Thus far, we have only considered estimated effects of
implementing both interventions, indicating public
health-relevant effects on BP and premature mortality
(as all calculations were restricted to people aged 40–65
years). Others have shown effects on wider outcomes as
well (see [34] for effects on BP-attributable hospitaliza-
tions; Organisation for Economic Co-operation and De-
velopment [87] for estimating and comparing effects on
alcohol interventions on disease burden). For any change
in healthcare systems, information about costs are also
necessary, as effective interventions may not be taken up
if they are not cost-effective. A recent systematic review
showed that brief interventions in primary healthcare
have also been shown to be cost-effective [88]. In
addition, Angus et al. [89] estimated, by modelling po-
tential effects of implementing screening and brief inter-
ventions for hazardous or harmful drinking, that these
programs were likely to be cost-effective in 24 out of 28
European Union countries and cost-saving in 50% of
these. They concluded that implementing national alco-
hol intervention programs in primary healthcare would
be a cost-effective means to reduce health burden. How-
ever, it should be noted that the work of Angus et al.
[89] was not limited to the consequences mediated by
BP, but included all health consequences.
Given these numbers, and bearing in mind that there is
only one best buy for hypertension (Appendix 3 of [1])
and, further, that the three best buys for alcohol have been
rarely considered by decision-makers given the strong im-
pact of economic operators and the fear that taxation in-
creases and availability restrictions would prove unpopular
with many voters [90], implementing alcohol interventions
for people with newly detected hypertension seems an at-
tractive and feasible option to improve public health at
relatively low, or for some jurisdictions, no overall costs.
Potential for implementation and conclusions
All of the four recommendations have been chosen as
measurable, achievable, and realistic for implementation
in primary healthcare. Obviously, as with all recommenda-
tions, implementations should be carefully evaluated.
While we have laid out the economic arguments for
implementing the recommendations, these are currently
based on assumptions and different modelling approaches.
More controlled approaches with randomization should
be used to study the effects of the recommendations.
Moreover, evaluations, including but not limited to eco-
nomic evaluations [91], are necessary to create sustainable
policies, which could be defended in times of scarce
resources.
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During implementation, priority should be given to the
integration of routine screening for alcohol (recommenda-
tion 2) and interventions for hazardous and harmful drink-
ing (recommendation 2) and AUDs (recommendation 3)
into the management of hypertension. Improved training
and better remuneration systems, specifically adapted to
the different healthcare systems, are crucial [57]. Some of
the current steps in this direction are promising, and we
hope that the reasoning and recommendations of this con-
sensus paper can provide further important momentum to
move European healthcare systems in this direction.
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